Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sodium chloride solution 0.9% (saline) Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Vitamin B12 Treatment in Singers

NCT03437824
View directory record Official record
Conditions
Vitamin B 12 Deficiency
Interventions
Cyanocobalamin, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Povidone-Iodine for Nasal Decolonization

NCT05529173
View directory record Official record
Conditions
Surgical Wound Infection, Preoperative Care, Methicillin-Resistant Staphylococcus Aureus
Interventions
Povidone-Iodine 10%, 0.9% NaCl Solution
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 1Phase 2 Interventional

ST266 Versus Standard Care In Treating Partial Thickness Burns

NCT00886470
View directory record Official record
Conditions
Burns
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
14
States / cities
Mobile, Alabama • Los Angeles, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

NCT00534313
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
19
States / cities
Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

NCT00670410
View directory record Official record
Conditions
Neuroblastoma
Interventions
Related donor transplant, Cord blood transplant, Busulfan, Thymoglobulin, Fludarabine
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

NCT01381562
View directory record Official record
Conditions
Infections, Intestinal
Interventions
Drug: GSK2251052, Meropenem, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery

NCT04333095
View directory record Official record
Conditions
Cardiovascular Surgery, Pain, Postoperative, Block
Interventions
Liposomal bupivacaine, Normal Saline Flush, 0.9% Injectable Solution_#1
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 14, 2026, 6:50 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections

NCT02469857
View directory record Official record
Conditions
Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene
Interventions
AB103 0.5 mg/kg, NaCl 0.9%
Drug · Other
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
12 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

NCT03836664
View directory record Official record
Conditions
Migraine
Interventions
Timolol, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 14, 2026, 6:50 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Valproic AcId for Traumatic BRAin INjury Trial

NCT07166393
View directory record Official record
Conditions
Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Interventions
Valproic Acid (VPA), Standard of care treatment + normal saline
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
8
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03848845
View directory record Official record
Conditions
Multiple Myeloma
Interventions
belantamab mafodotin, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 14, 2026, 6:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

NCT06282965
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Angiotensin (1-7), Sterile saline
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

NCT03040011
View directory record Official record
Conditions
Pelvic Organ Prolapse, Surgery, Postoperative Pain
Interventions
Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline
Drug · Procedure
Lead sponsor
Lauren Giugale, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition

NCT02227329
View directory record Official record
Conditions
Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter, Bloodstream Infection Due to Hickman Catheter
Interventions
Ethanol, Heparin Lock, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 14, 2026, 6:50 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair

NCT03219580
View directory record Official record
Conditions
Brow Ptosis, Facial Scarring
Interventions
5-Fluorouracil, Normal Saline Flush, 0.9% Injectable Solution
Drug
Lead sponsor
Eyelid and Facial Consultants
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Houma, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension

NCT01520207
View directory record Official record
Conditions
Intra-dialytic Hypotension
Interventions
Mannitol (20%), 0.9% saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 14, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Corticosteroids to Treat Pancreatitis

NCT05160506
View directory record Official record
Conditions
Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation

NCT02162433
View directory record Official record
Conditions
Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Tonsillitis, Adenoiditis
Interventions
Normal Saline, Dexmedetomidine
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
3 Years to 16 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 14, 2026, 6:50 AM EDT